The burgeoning popularity of semaglutide , initially for blood sugar control , is creating significant buzz within the British Isles, prompting a notable shift in peptide trends. Access these treatments remains a complex situation , with NHS approval currently limited and specialist practices offering treatment at a higher cost . Questions are bein